

Feby Savira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2578414/publications.pdf>

Version: 2024-02-01

18
papers

240
citations

1039880

9
h-index

996849

15
g-index

19
all docs

19
docs citations

19
times ranked

379
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 975-982.	0.8	35
2	RE: Inhibition of apoptosis signal-regulating kinase 1 might be a novel therapeutic target in the treatment of cardiorenal syndrome. <i>International Journal of Cardiology</i> , 2021, 323, 260.	0.8	0
3	The Preventable Productivity Burden of Kidney Disease in Australia. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 938-949.	3.0	6
4	RE: Blockade of apoptosis signal-regulating kinase 1 ameliorates cardiac dysfunction in cardiorenal syndrome via enhancing angiogenesis. <i>International Journal of Cardiology</i> , 2021, 326, 156.	0.8	0
5	Apoptosis signal-regulating kinase 1 inhibition reverses deleterious indoxyl sulfate-mediated endothelial effects. <i>Life Sciences</i> , 2021, 272, 119267.	2.0	7
6	Attenuating PI3K/Akt- mTOR pathway reduces dihydrosphingosine 1 phosphate mediated collagen synthesis and hypertrophy in primary cardiac cells. <i>International Journal of Biochemistry and Cell Biology</i> , 2021, 134, 105952.	1.2	18
7	Dihydrosphingosine driven enrichment of sphingolipids attenuates TGF β ² induced collagen synthesis in cardiac fibroblasts. <i>IJC Heart and Vasculature</i> , 2021, 35, 100837.	0.6	3
8	The effect of dihydroceramide desaturase 1 inhibition on endothelial impairment induced by indoxyl sulfate. <i>Vascular Pharmacology</i> , 2021, 141, 106923.	1.0	4
9	Sphingolipid imbalance and inflammatory effects induced by uremic toxins in heart and kidney cells are reversed by dihydroceramide desaturase 1 inhibition. <i>Toxicology Letters</i> , 2021, 350, 133-142.	0.4	7
10	The impact of coronary heart disease prevention on work productivity: a 10-year analysis. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 418-425.	0.8	11
11	RE: ASK1, a new target in treating cardiorenal syndrome (CRS). <i>International Journal of Cardiology</i> , 2020, 316, 207.	0.8	0
12	Exogenous dihydrosphingosine 1 phosphate mediates collagen synthesis in cardiac fibroblasts through JAK/STAT signalling and regulation of TIMP1. <i>Cellular Signalling</i> , 2020, 72, 109629.	1.7	15
13	Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. <i>British Journal of Pharmacology</i> , 2020, 177, 2906-2922.	2.7	46
14	Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome. <i>International Journal of Cardiology</i> , 2020, 310, 128-136.	0.8	10
15	Molecular mechanisms of protein-bound uremic toxin-mediated cardiac, renal and vascular effects: underpinning intracellular targets for cardiorenal syndrome therapy. <i>Toxicology Letters</i> , 2019, 308, 34-49.	0.4	12
16	The role of dihydrosphingolipids in disease. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1107-1134.	2.4	31
17	Inhibition of Apoptosis Signal-Regulating Kinase 1 Attenuates Myocyte Hypertrophy and Fibroblast Collagen Synthesis. <i>Heart Lung and Circulation</i> , 2019, 28, 495-504.	0.2	9
18	Apoptosis signal-regulating kinase 1 inhibition attenuates cardiac hypertrophy and cardiorenal fibrosis induced by uremic toxins: Implications for cardiorenal syndrome. <i>PLoS ONE</i> , 2017, 12, e0187459.	1.1	26